Batavia Biosciences

Cellevate is an innovative biotech company that develops the next generation of cell culture systems. Through a patented manufacturing process we create highly porous networks of polymer nanofibers. The fibers aim to provide an environment which accurately resembles the complex surroundings cells experience in their native tissues. Cells in these networks are allowed to proliferate and interact with other cells in three dimensions (3D), in contrast to the monolayer cultures seen on conventional two dimensional (2D) surfaces. Cellevate put great emphasis on consistency and compatibility with today's analysis equipment to facilitate a quick and simple changeover from 2D to 3D culturing.

Abliance masters essential technologies to develop new generation antibodies. Our team of experts closely works with research laboratories, diagnostic industry, actors of clinical research and biopharmaceutical industry to understand the needs associated with each application, its regulatory environment and economic constraints. Abliance provides antibodies that perform in their application by designing unique solutions.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Created in 1990 and funded by AFM-TELETHON, Genethon, a pioneer in deciphering the human genome and identifying the genes associated with genetic diseases is today fully dedicated to the design and development of gene therapy treatments for rare diseases.

At Genethon more than 180 scientists, clinicians and engineers specialized in gene therapy drug development, from research to the clinic, have joined forces in order to provide these innovative treatments to patients affected with rare disorders. These treatments also pave the way for new therapeutic approaches for frequent disorders.

In 2012 Genethon received the Prix Galien France for pharmaceutical research into “Medicines destined for rare diseases – cell therapy and gene therapy.”

In 2013 Genethon’s production facility, Genethon BioProd obtained certification as a pharmaceutical manufacturer from French National agency for medicines and health products safety (ANSM). Genethon BioProd is the largest laboratory for GMP production of gene therapy products in the world.

In april 2015 Genethon was recipient of the Global Innovation Competition 2030 in the category “Risk Lift” at the Elysee Palace, for its project on the development of an industrial process for production of gene therapy vectors.

Phytopharm, member of Europlant Group, is a pharmaceutical company found in 1949. We specialize in development and manufacturing of natural medicines, food supplements, medical devices, cosmetics and herbal extracts.

We develop and produce the highest quality products of plant origin with proven effectiveness and confirmed safety in majority based on our own APIs and extracts produced from dry and fresh herbs.

We also provide a wide range of B2B services including:
- contract manufacturing,
- product development and
- out-licensing for our own products with a complete registration documentation.

The expertise in natural medicines, modern production plant, GMP and ISO standards make Phytopharm a reliable partner.